BR112018013364A2 - forma cristalina e composição farmacêutica - Google Patents

forma cristalina e composição farmacêutica

Info

Publication number
BR112018013364A2
BR112018013364A2 BR112018013364A BR112018013364A BR112018013364A2 BR 112018013364 A2 BR112018013364 A2 BR 112018013364A2 BR 112018013364 A BR112018013364 A BR 112018013364A BR 112018013364 A BR112018013364 A BR 112018013364A BR 112018013364 A2 BR112018013364 A2 BR 112018013364A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
crystalline form
crystalline forms
methylpiperazin
thieno
Prior art date
Application number
BR112018013364A
Other languages
English (en)
Inventor
Joo Kwak Eun
Cheol Kim Hee
Hyuk Jung Jae
Ouk Baek Jong
Young Jung Sun
Hee Ha Tae
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112018013364A2 publication Critical patent/BR112018013364A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

a presente invenção se refere a formas cristalinas de n-(3-(2-(4-(4-metilpiperazin-1-il)fenilamino)tieno[3,2-d]pirimidin-4-iloxi)fenil)acrilamida, e composições farmacêuticas que contêm a mesma. as formas cristalinas podem ser facilmente usadas para a preparação de uma composição farmacêutica que contém a mesma como um ingrediente ativo.
BR112018013364A 2015-12-31 2016-12-30 forma cristalina e composição farmacêutica BR112018013364A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150190854 2015-12-31
PCT/KR2016/015536 WO2017116193A1 (en) 2015-12-31 2016-12-30 Crystalline forms of thienopyrimidine compound

Publications (1)

Publication Number Publication Date
BR112018013364A2 true BR112018013364A2 (pt) 2018-12-04

Family

ID=59225209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013364A BR112018013364A2 (pt) 2015-12-31 2016-12-30 forma cristalina e composição farmacêutica

Country Status (16)

Country Link
US (1) US10464946B2 (pt)
EP (1) EP3380482A4 (pt)
JP (1) JP2019504046A (pt)
KR (1) KR20180089904A (pt)
CN (1) CN108473507A (pt)
AU (1) AU2016382385A1 (pt)
BR (1) BR112018013364A2 (pt)
CA (1) CA3010315A1 (pt)
HK (1) HK1252842A1 (pt)
IL (1) IL259982A (pt)
MX (1) MX2018008005A (pt)
PH (1) PH12018501331A1 (pt)
RU (1) RU2018122825A (pt)
SG (1) SG11201804860YA (pt)
TW (1) TW201726686A (pt)
WO (1) WO2017116193A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170050453A (ko) * 2015-10-30 2017-05-11 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체
MX2018008006A (es) 2015-12-31 2019-03-14 Hanmi Pharm Ind Co Ltd Formas cristalinas de sales clorhidrato de compuesto de tienopirimidina.
KR20200114776A (ko) * 2019-03-29 2020-10-07 한미약품 주식회사 퓨로피리미딘 화합물의 산 부가염의 결정형

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY162132A (en) * 2010-06-23 2017-05-31 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2015112705A2 (en) 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
WO2016025641A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and an egfr inhibitor and related methods
US10040801B2 (en) * 2014-12-30 2018-08-07 Hanmi Pharm. Co., Ltd. Method for preparing thienopyrimidine compound and intermediates used therein
KR20170050453A (ko) * 2015-10-30 2017-05-11 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체

Also Published As

Publication number Publication date
AU2016382385A1 (en) 2018-07-12
PH12018501331A1 (en) 2019-02-18
SG11201804860YA (en) 2018-07-30
CN108473507A (zh) 2018-08-31
US10464946B2 (en) 2019-11-05
RU2018122825A3 (pt) 2020-02-28
WO2017116193A1 (en) 2017-07-06
KR20180089904A (ko) 2018-08-09
IL259982A (en) 2018-07-31
JP2019504046A (ja) 2019-02-14
TW201726686A (zh) 2017-08-01
EP3380482A1 (en) 2018-10-03
CA3010315A1 (en) 2017-07-06
MX2018008005A (es) 2019-03-14
HK1252842A1 (zh) 2019-06-06
US20190016733A1 (en) 2019-01-17
EP3380482A4 (en) 2019-05-15
RU2018122825A (ru) 2020-02-04

Similar Documents

Publication Publication Date Title
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CL2018001031A1 (es) Inhibidores de ferroportina novedosos
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112014011938A2 (pt) combinação de formulação de dois compostos antivirais
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
PH12016502461A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
BR112017004948A2 (pt) formulação farmacêutica.
BR112018013364A2 (pt) forma cristalina e composição farmacêutica
BR112018013356A2 (pt) sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112017012558A2 (pt) Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas
BR112017014295A2 (pt) composição farmacêutica.
EA201690236A1 (ru) Производные индол-3-карбинола
BR112018005377A2 (pt) método para preparar uma formulação estável
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
DOP2016000322A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 495/04

Ipc: C07D 495/04 (2006.01), A61K 31/55 (2006.01), A61K

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements